The Association Between Medication Adherence for Chronic Conditions and Digital Health Activity Tracking: Retrospective Analysis.


Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
20 03 2019
Historique:
received: 04 07 2018
accepted: 31 12 2018
revised: 13 12 2018
entrez: 21 3 2019
pubmed: 21 3 2019
medline: 8 2 2020
Statut: epublish

Résumé

Chronic diseases have a widespread impact on health outcomes and costs in the United States. Heart disease and diabetes are among the biggest cost burdens on the health care system. Adherence to medication is associated with better health outcomes and lower total health care costs for individuals with these conditions, but the relationship between medication adherence and health activity behavior has not been explored extensively. The aim of this study was to examine the relationship between medication adherence and health behaviors among a large population of insured individuals with hypertension, diabetes, and dyslipidemia. We conducted a retrospective analysis of health status, behaviors, and medication adherence from medical and pharmacy claims and health behavior data. Adherence was measured in terms of proportion of days covered (PDC), calculated from pharmacy claims using both a fixed and variable denominator methodology. Individuals were considered adherent if their PDC was at least 0.80. We used step counts, sleep, weight, and food log data that were transmitted through devices that individuals linked. We computed metrics on the frequency of tracking and the extent to which individuals engaged in each tracking activity. Finally, we used logistic regression to model the relationship between adherent status and the activity-tracking metrics, including age and sex as fixed effects. We identified 117,765 cases with diabetes, 317,340 with dyslipidemia, and 673,428 with hypertension between January 1, 2015 and June 1, 2016 in available data sources. Average fixed and variable PDC for all individuals ranged from 0.673 to 0.917 for diabetes, 0.756 to 0.921 for dyslipidemia, and 0.756 to 0.929 for hypertension. A subgroup of 8553 cases also had health behavior data (eg, activity-tracker data). On the basis of these data, individuals who tracked steps, sleep, weight, or diet were significantly more likely to be adherent to medication than those who did not track any activities in both the fixed methodology (odds ratio, OR 1.33, 95% CI 1.29-1.36) and variable methodology (OR 1.37, 95% CI 1.32-1.43), with age and sex as fixed effects. Furthermore, there was a positive association between frequency of activity tracking and medication adherence. In the logistic regression model, increasing the adjusted tracking ratio by 0.5 increased the fixed adherent status OR by a factor of 1.11 (95% CI 1.06-1.16). Finally, we found a positive association between number of steps and adherent status when controlling for age and sex. Adopters of digital health activity trackers tend to be more adherent to hypertension, diabetes, and dyslipidemia medications, and adherence increases with tracking frequency. This suggests that there may be value in examining new ways to further promote medication adherence through programs that incentivize health tracking and leveraging insights derived from connected devices to improve health outcomes.

Sections du résumé

BACKGROUND
Chronic diseases have a widespread impact on health outcomes and costs in the United States. Heart disease and diabetes are among the biggest cost burdens on the health care system. Adherence to medication is associated with better health outcomes and lower total health care costs for individuals with these conditions, but the relationship between medication adherence and health activity behavior has not been explored extensively.
OBJECTIVE
The aim of this study was to examine the relationship between medication adherence and health behaviors among a large population of insured individuals with hypertension, diabetes, and dyslipidemia.
METHODS
We conducted a retrospective analysis of health status, behaviors, and medication adherence from medical and pharmacy claims and health behavior data. Adherence was measured in terms of proportion of days covered (PDC), calculated from pharmacy claims using both a fixed and variable denominator methodology. Individuals were considered adherent if their PDC was at least 0.80. We used step counts, sleep, weight, and food log data that were transmitted through devices that individuals linked. We computed metrics on the frequency of tracking and the extent to which individuals engaged in each tracking activity. Finally, we used logistic regression to model the relationship between adherent status and the activity-tracking metrics, including age and sex as fixed effects.
RESULTS
We identified 117,765 cases with diabetes, 317,340 with dyslipidemia, and 673,428 with hypertension between January 1, 2015 and June 1, 2016 in available data sources. Average fixed and variable PDC for all individuals ranged from 0.673 to 0.917 for diabetes, 0.756 to 0.921 for dyslipidemia, and 0.756 to 0.929 for hypertension. A subgroup of 8553 cases also had health behavior data (eg, activity-tracker data). On the basis of these data, individuals who tracked steps, sleep, weight, or diet were significantly more likely to be adherent to medication than those who did not track any activities in both the fixed methodology (odds ratio, OR 1.33, 95% CI 1.29-1.36) and variable methodology (OR 1.37, 95% CI 1.32-1.43), with age and sex as fixed effects. Furthermore, there was a positive association between frequency of activity tracking and medication adherence. In the logistic regression model, increasing the adjusted tracking ratio by 0.5 increased the fixed adherent status OR by a factor of 1.11 (95% CI 1.06-1.16). Finally, we found a positive association between number of steps and adherent status when controlling for age and sex.
CONCLUSIONS
Adopters of digital health activity trackers tend to be more adherent to hypertension, diabetes, and dyslipidemia medications, and adherence increases with tracking frequency. This suggests that there may be value in examining new ways to further promote medication adherence through programs that incentivize health tracking and leveraging insights derived from connected devices to improve health outcomes.

Identifiants

pubmed: 30892271
pii: v21i3e11486
doi: 10.2196/11486
pmc: PMC6446150
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e11486

Commentaires et corrections

Type : ErratumIn

Informations de copyright

©Tom Quisel, Luca Foschini, Susan M Zbikowski, Jessie L Juusola. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 20.03.2019.

Références

Patient Prefer Adherence. 2013 Jun 12;7:509-16
pubmed: 23807840
J Manag Care Pharm. 2014 Jan;20(1):51-7
pubmed: 24372460
Risk Manag Healthc Policy. 2014 Feb 20;7:35-44
pubmed: 24591853
J Manag Care Spec Pharm. 2016 Jan;22(1):63-73
pubmed: 27015053
J Manag Care Spec Pharm. 2014 Jul;20(7):703-13
pubmed: 24967523
Am J Manag Care. 2010 Aug;16(8):568-76
pubmed: 20712390
Diabetes Care. 2013 Apr;36(4):1033-46
pubmed: 23468086
Circulation. 2014 Jan 21;129(3):e28-e292
pubmed: 24352519
Prev Chronic Dis. 2014 Apr 17;11:E62
pubmed: 24742395
Am J Epidemiol. 2007 Aug 1;166(3):348-54
pubmed: 17504779
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
Patient Prefer Adherence. 2016 Aug 16;10:1573-81
pubmed: 27574406
Health Aff (Millwood). 2011 Jan;30(1):91-9
pubmed: 21209444
Value Health. 2007 Jan-Feb;10(1):3-12
pubmed: 17261111
J Med Internet Res. 2014 Oct 30;16(10):e233
pubmed: 25356929
BMJ. 2006 Jul 1;333(7557):15
pubmed: 16790458
Hypertension. 2006 Jun;47(6):1039-48
pubmed: 16651464

Auteurs

Tom Quisel (T)

Evidation Health, San Mateo, CA, United States.

Luca Foschini (L)

Evidation Health, San Mateo, CA, United States.

Susan M Zbikowski (SM)

inZights Consulting, LLC, Seattle, WA, United States.
Humana, Inc, Louisville, KY, United States.

Jessie L Juusola (JL)

Evidation Health, San Mateo, CA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH